 This crossover study will assess the effect of 2 doses of Taspoglutide on first- and second-phase insulin secretion in patients with type 2 diabetes. Patients will receive a continuous subcutaneous infusion of athe Immediate Release Formulation IRFof Taspoglutide 300 microgramsday for 2 days followed by Taspoglutide 800 microgramsday for 2 days or bsaline placebo for 22 days. After a washout period of 10-15 days, patients will be crossed-over for further treatment;those receiving Taspoglutide in period 1 will receive placebo in period 2, and vice versa. On days 2 and 4 of each period, insulin secretion patterns will be assessed. The anticipated time on study treatment is 3 months, and the target sample size is 100 individuals. 